Company profile: Merck
1.1 - Company Overview
Company description
- Provider of life science, healthcare, and electronics solutions in the U.S. and Canada as EMD Serono, MilliporeSigma, and EMD Electronics. Supplies lab chemicals, solvents, materials, and tools; process solutions for drug development; end-to-end testing, analytics, and manufacturing support; develops medicines and devices for cancer, multiple sclerosis, fertility, and endocrine disorders; and materials/equipment for semiconductors, displays, and surfaces.
Products and services
- Electronics: Delivers semiconductor-grade materials, equipment, and services for semiconductor systems, display systems, and surface systems, architecting technology advances across industries through targeted materials and equipment portfolios
- Healthcare: Develops medicines and devices for cancer, multiple sclerosis, fertility, and endocrine disorders to improve patient care and treatment outcomes, producing clinical-grade therapeutics and devices
- Life Science: Supplies tools and services for scientific research and engineering, integrating lab systems, process assemblies, and life science services—testing, analytics, manufacturing support, upstream/downstream processing, filtration and purification—via modular architectures
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Merck
LP Pharmaceuticals
HQ: China
Website
- Description: Provider of pharmaceuticals.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full LP Pharmaceuticals company profile →
Plexxikon
HQ: United States
Website
- Description: Provider of small molecule pharmaceuticals focused on discovering and developing therapies for human diseases. Portfolio includes Zelboraf for BRAF V600E–mutant skin cancer, Turalio for tenosynovial giant cell tumor (TGCT), and personalized medicines. Pipeline candidates include PLX204 for diabetes, PLX4032 for melanoma and colorectal cancer, and PLX5568 kinase inhibitors for pain and polycystic kidney disease.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Plexxikon company profile →
Omeros
HQ: United States
Website
- Description: Provider of clinical-stage biopharmaceutical therapies for inflammation and central nervous system disorders, including MASP-2 antibodies (narsoplimab, OMS1029) for lectin pathway diseases such as TA-TMA and lupus nephritis; MASP-3 antibody (OMS906) for PNH; small-molecule PDE7 (OMS527) and PPARγ (OMS405) candidates for addiction; and GPR174 inhibitors for cancer immunotherapy.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Omeros company profile →
TiGenix
HQ: Belgium
Website
- Description: Provider of innovative local regenerative medicine treatments for damaged and osteoarthritic joints, focusing on research and development of durable therapies validated through controlled clinical studies.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full TiGenix company profile →
Vicore Pharma
HQ: Sweden
Website
- Description: Provider of pharmaceuticals for severe lung disorders, developing drugs acting through the angiotensin II type 2 (AT2) receptor, including buloxibutid (C21), an orally available ATRAG in phase 2a for idiopathic pulmonary fibrosis (IPF) with orphan drug designation in the EU, and Almee, a digital therapeutic based on cognitive behavioral therapy to address the psychological impact of pulmonary fibrosis.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Vicore Pharma company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Merck
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Merck
2.2 - Growth funds investing in similar companies to Merck
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Merck
4.2 - Public trading comparable groups for Merck
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →